Overview

Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This is a single centre, open-label phase I trial to investigate the effects of moderate to severe hepatic impairment on the pharmacokinetics of prucalopride in comparison with healthy volunteers. Furthermore the short-term safety and tolerability of a single dose of prucalopride will be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Movetis
Treatments:
Prucalopride